MicroRNA-155 from sputum as noninvasive biomarker for diagnosis of active pulmonary tuberculosis

Document Type: Original Article

Authors

1 Vascular Disease Research Center and Basic Medical Laboratory, the Second affiliated hospital of Wannan Medical College, Kangfu Road 10#, Wuhu 241000, Anhui province, PR China

2 School of Nursing, Wannan Medical College, Wenchang Xi Road 22#, Wuhu 241000, Anhui province, PR China

3 Department of clinical laboratory, the Second peoples’ hospital of Wuhu city, Jiuhua Zhong Road 259#, Wuhu 241000, Anhui province, PR China

4 Department of microbiology, Wannan Medical College, Wenchang Xi Road 22#, Wuhu 241000, Anhui province, PR China

10.22038/ijbms.2020.44029.10324

Abstract

Objective(s): Tuberculosis (TB), caused by Mycobacterium tuberculosis, is a widespread infectious disease around the world. Early diagnosis is always important in order to avoid spreading. At present, many studies have confirmed that microRNA (miRNA) could be a useful tool for diagnosis. This study aimed to evaluate whether miRNAs could be regarded as a noninvasive diagnosis biomarker from sputum for pulmonary tuberculosis (PTB).
Materials and Methods: The M. tuberculosis strain H37Rv was incubated and cultured with human macrophage line THP-1. The total RNA was extracted from the THP-1 cells for detection. Six increased expressions of miRNAs were selected by miRNA microarray chips and the miRNAs were confirmed by qRT-PCR in the M. tuberculosis infection cell model. At last, the efficiency of other methods was compared with using miRNA.
Results: Only miR-155 showed a better diagnostic value for PTB than the other five miRNAs to distinguish PTB from non-PTB, including pneumonia, lung cancer, and unexplained pulmonary nodules. Next, we detected and analyzed the results of 68 PTB patients and 122 non-PTB, the sensitivity and specificity of miR-155 detection was 94.1% and 87.7%, respectively. It was higher than sputum smear detection and anti-TB antibody detection. But slightly lower than ELISpot (97%, P=0.404). Interestingly, the ranking of sputum smear by Ziehl-Neelsen staining had positive correlation with the expression level of miR-155 in smear-positive sputum (R2=0.8443, p <0.05).
Conclusion: Our research suggested that miR-155 may be an efficiency biomarker for active PTB diagnosis and bacteria-loads evaluation.

Keywords


1. Forrellad MA, Klepp LI, Gioffre A, Sabio y Garca J, Morbidoni HR, de la Paz Santangelo M, et al. Virulence factors of the Mycobacterium tuberculosis complex. Virulence 2013; 4:3-66.
2. Fang Z, van der Merwe RG, Warren RM, Schubert WD, Gey van Pittius NC. Assessing the progress of Mycobacterium tuberculosis H37Rv structural genomics. Tuberculosis (Edinb) 2015; 95:131-136.
3. World Health Organization. World Health Organization press release. WHO sees surge in progress against tuberculosis on eve of global summit. Saudi Med J 2004; 25:1140-1141.
4. Wallis RS, Pai M, Menzies D, Doherty TM, Walzl G, Perkins MD, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010; 375:1920-1937.
5. Magalhães J, Lima J, Araújo AA, Coutinho IO, Leal NC, Almeida A. Microscopic detection of Mycobacterium tuberculosis in direct or processed sputum smears. Rev Soc Bras Med Trop 2018; 51:237-239.
6. Lourens M, Philips L, Kleinhans CC, Friedrich SO, Martinson N, Venter A, et al. Liquid mycobacterial culture outcomes after different sputum collection techniques before and during treatment.Tuberculosis (Edinb) 2019; 116:17-21, .
7. Kim VN, Nam JW. Genomics of microRNA. Trends Genet 2006; 22:165-173.
8. Li J, Zou X. MiR-652 serves as a prognostic biomarker in gastric cancer and promotes tumor proliferation, migration, and invasion via targeting RORA. Cancer Biomark 2019; 26:323-331.
9. Liu Y, Wang X, Jiang J, Cao Z, Yang B, Cheng X. Modulation of T cell cytokine production by miR-144* with elevated expression in patients with pulmonary tuberculosis. Mol Immunol 2011; 48:1084-1090.
10. Acunzo M, Croce CM. MicroRNA in Cancer and Cachexia--A Mini-Review. J Infect Dis 2015; 212 Suppl 1:S74-77.
11. Lyu J, Zhao L, Wang F, Ji J, Cao Z, Xu H, et al. Discovery and validation of serum micrornas as early diagnostic biomarkers for prostate cancer in Chinese population. Biomed Res Int 2019; 2019:9306803.
12. Santamaria-Martos F, Benítez I, Ortega F, Zapater A, Giron C, Pinilla L, et al. Circulating microRNA profile as a potential biomarker for obstructive sleep apnea diagnosis. Sci Rep 2019; 9:13456.
13. Záveský L, Jandáková E, Weinberger V, Minář L, Hanzíková V, Dušková D, et al. Ovarian cancer: Differentially expressed microRNAs in tumor tissue and cell-free ascitic fluid as potential novel biomarkers. Cancer Invest 2019; 18:1-13.
14. Hofbauer SL, de Martino M, Lucca I, Haitel A, Susani M, Shariat SF, et al. A urinary microRNA (miR) signature for diagnosis of bladder cancer. Urol Oncol 2018; 36:531.e1-531.e8.
15. Ndzi EN, Nkenfou CN, Mekue LM, Zentilin L, Tamgue O, Pefura E, et al. MicroRNA hsa-miR-29a-3p is a plasma biomarker for the differential diagnosis and monitoring of tuberculosis. Tuberculosis (Edinb) 2019;114:69-76.
16. Lv Y, Guo S, Li XG, Chi JY, Qu YQ, Zhong HL. Sputum and serum microRNA-144 levels in patients with tuberculosis before and after treatment. Int J Infect Dis 2016;43:68-73.
17. Zheng ML, Zhou NK, Luo CH. MiRNA-155 and miRNA-132 as potential diagnostic biomarkers for pulmonary tuberculosis: A preliminary study. Microb Pathog 2016;100:78-83.
18. Lacedonia D, Palladino GP, Foschino-Barbaro MP, Scioscia G, Carpagnano GE. Expression profiling of miRNA-145 and miRNA-338 in serum and sputum of patients with COPD, asthma, and asthma-COPD overlap syndrome phenotype. Int J Chron Obstruct Pulmon Dis 2017; 12:1811-1817.
19. Zhang X, Wang Q, Zhang S. MicroRNAs in sputum specimen as noninvasive biomarkers for the diagnosis of nonsmall cell lung cancer: An updated meta-analysis. Medicine (Baltimore) 2019; 98:e14337.
20. Su Y, Guarnera MA, Fang H, Jiang F. Small non-coding RNA biomarkers in sputum for lung cancer diagnosis. Mol Cancer 2016; 15:36.
21. World Health Organization, International Union Against Tuberculosis and Lung Disease, Royal Netherlands Tuberculosis Association. Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis 2001; 5:213-215.
22. Sloane AJ, Lindner RA, Prasad SS, Sebastian LT, Pedersen SK, Robinson M, et al. Proteomic analysis of sputum from adults and children with cystic fibrosis and from control subjects. Am J Respir Crit Care Med 2005; 172:1416-1426.
23. Sagel SD, Kapsner R, Osberg I, Sontag MK, Accurso FJ. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am J Respir Crit Care Med 2001;164:1425-1431.
24. Tang XL, Yuan CH, Ding Q, Zhou Y, Pan Q, Zhang XL. Selection and identification of specific glycoproteins and glycan biomarkers of macrophages involved in Mycobacterium tuberculosis infection. Tuberculosis (Edinb) 2017;104:95-106.
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-408.
26. Dye C, Williams BG. The population dynamics and control of tuberculosis. Science 2010;328:856-861.
27. Shi QN, Ma JQ. [Big data analysis of flow of tuberculosis cases in China, 2014]. Zhonghua Liu Xing Bing Xue Za Zhi 2016; 37:668-672.
28. Sharbati J, Lewin A, Kutz-Lohroff B, Kamal E, Einspanier R, Sharbati S. Integrated microRNA-mRNA-analysis of human monocyte derived macrophages upon Mycobacterium avium subsp. hominissuis infection. PLoS One 2011;6:e20258.
29. Furci L, Schena E, Miotto P, Cirillo DM. Alteration of human macrophages microRNA expression profile upon infection with Mycobacterium tuberculosis. Int J Mycobacteriol 2013;2:128-134.
30. Backes C, Meese E, Keller A. Specific miRNA disease biomarkers in blood, serum and plasma: Challenges and prospects. Mol Diagn Ther 2016;20:509-518.
31. Dieter C, Assmann TS, Costa AR, Canani LH, de Souza BM, Bauer AC, et al. MiR-30e-5p and MiR-15a-5p expressions in plasma and urine of type 1 diabetic patients with diabetic kidney disease. Front Genet 2019;10:563.
32. Yu L, Todd NW, Xing L, Xie Y, Zhang H, Liu Z, et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer 2010;127:2870-2878.
33. Xie Y, Todd NW, Liu Z, Zhan M, Fang H, Peng H, et al. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer 2010;67:170-176.
34. Maes T, Cobos FA, Schleich F, Sorbello V, Henket M, De Preter K, et al. Asthma inflammatory phenotypes show differential microRNA expression in sputum. J Allergy Clin Immunol 2016;137:1433-1446.
35. Bagheri A, Khorram Khorshid HR, Mowla SJ, Mohebbi HA, Mohammadian A, Yaseri M, et al. Altered miR-223 expression in sputum for diagnosis of non-small cell lung cancer. Avicenna J Med Biotechnol 2017;9:189-195.
36. Zhengjun Yi, Yurong Fu, Rui Ji, Ruifang Li, Zhiyu Guan.Altered microRNA signatures in sputum of patients with active pulmonary tuberculosis. PLoS One 2012; 7:e43184.
37. Wu J, Lu C, Diao N, Zhang S, Wang S, Wang F, et al. Analysis of microRNA expression profiling identifies miR-155 and miR-155* as potential diagnostic markers for active tuberculosis: a preliminary study. Hum Immunol 2012;73:31-37.
38. Huang J, Jiao J, Xu W, Zhao H, Zhang C, Shi Y, et al. MiR-155 is upregulated in patients with active tuberculosis and inhibits apoptosis of monocytes by targeting FOXO3. Mol Med Rep 2015;12:7102-7108.
39. Dudda JC, Salaun B, Ji Y, Palmer DC, Monnot GC, Merck E, et al. MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity 2013;38:742-753.
40. Huffaker TB, Hu R, Runtsch MC, Bake E, Chen X, Zhao J, et al. Epistasis between microRNAs 155 and 146a during T cell-mediated antitumor immunity. Cell Rep 2012;2:1697-1709.